Table 3.
The distribution of genotype frequencies of TLR SNPs in healthy women and those with HGSOC subtype.
| Gene SNP |
Model | Genotype | Genotype Frequencies, n (%) a | Unadjusted | Adjusted b | Adjusted c | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls | Cases | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
| TLR4 | Codominant | AA | 128 (98.5) | 29 (72.5) | 1.00 | <0.0001 | 1.00 | 0.0001 | 1.00 | 0.002 |
| rs4986790 | AG | 2 (1.5) | 10 (25.0) | 22.07 (4.59–106.16) | 23.27 (4.63–116.92) | 13.47 (2.31–78.67) | ||||
| GG | 0 (0) | 1 (2.5) | NA (0.00–NA) | 3.34 (0.00–NA) | NA (0.00–NA) | |||||
| Dominant | AA | 128 (98.5) | 29 (72.5) | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | 0.0006 | |
| AG-GG | 2 (1.5) | 11 (27.5) | 24.28 (5.10–115.48) | 23.27 (4.63–116.92) | 16.84 (3.05–93.04) | |||||
| Recessive | AA-AG | 130 (100) | 39 (97.5) | 1.00 | 0.088 | 1.00 | 1 | 1.00 | 0.053 | |
| GG | 0 (0) | 1 (2.5) | NA (0.00–NA) | 2.42 (0.00–NA) | NA (0.00–NA) | |||||
| Overdominant | AA-GG | 128 (98.5) | 30 (75.0) | 1.00 | <0.0001 | 1.00 | <0.0001 | 1.00 | 0.0037 | |
| AG | 2 (1.5) | 10 (25.0) | 21.33 (4.44–102.48) | 23.27 (4.63–116.92) | 12.80 (2.20–74.52) | |||||
| TLR4 | Codominant | CC | 119 (91.54) | 37 (92.5) | 1.00 | 0.18 | 1.00 | 0.58 | 1.00 | 0.74 |
| rs4986791 | CT | 11 (8.5) | 2 (5.0) | 0.58 (0.12–2.76) | 0.37 (0.05–3.01) | 0.47 (0.06–3.82) | ||||
| TT | 0 (0) | 1 (2.5) | NA (0.00–NA) | 0.00 (0.00–NA) | 0.00 (0.00–NA) | |||||
| Dominant | CC | 119 (91.5) | 37 (92.5) | 1.00 | 0.85 | 1.00 | 0.29 | 1.00 | 0.44 | |
| CT-TT | 11 (8.5) | 3 (7.5) | 0.88 (0.23–3.31) | 0.37 (0.05–3.01) | 0.47 (0.06–3.82) | |||||
| Recessive | CC-CT | 130 (100) | 39 (97.5) | 1.00 | 0.088 | 1.00 | 1 | 1.00 | 1 | |
| TT | 0 (0) | 1 (2.5) | NA (0.00–NA) | 0.00 (0.00–NA) | 0.00 (0.00–NA) | |||||
| Overdominant | CC-TT | 119 (91.5) | 38 (95.0) | 1.00 | 0.45 | 1.00 | 0.29 | 1.00 | 0.44 | |
| CT | 11 (8.5) | 2 (5.0) | 0.57 (0.12–2.68) | 0.37 (0.05–3.01) | 0.47 (0.06–3.82) | |||||
| TLR9 | Codominant | TT | 35 (28.2) | 12 (30.8) | 1.00 | 0.094 | 1.00 | 0.13 | 1.00 | 0.72 |
| rs187084 | TC | 81 (65.3) | 20 (51.3) | 0.72 (0.32–1.63) | 0.60 (0.25–1.49) | 0.70 (0.27–1.84) | ||||
| CC | 8 (6.5) | 7 (17.9) | 2.55 (0.76–8.54) | 2.19 (0.58–8.19) | 1.09 (0.19–6.17) | |||||
| Dominant | TT | 35 (28.2) | 12 (30.8) | 1.00 | 0.76 | 1.00 | 0.51 | 1.00 | 0.53 | |
| TC-CC | 89 (71.8) | 27 (69.2) | 0.88 (0.40–1.94) | 0.75 (0.32–1.77) | 0.74 (0.29–1.89) | |||||
| Recessive | TT-TC | 116 (93.5) | 32 (82.0) | 1.00 | 0.043 | 1.00 | 0.084 | 1.00 | 0.70 | |
| CC | 8 (6.5) | 7 (17.9) | 3.17 (1.07–9.41) | 3.02 (0.91–10.04) | 1.38 (0.27–6.96) | |||||
| Overdominant | TT-CC | 43 (34.7) | 19 (48.7) | 1.00 | 0.12 | 1.00 | 0.092 | 1.00 | 0.42 | |
| TC | 81 (65.3) | 20 (51.3) | 0.56 (0.27–1.16) | 0.50 (0.22–1.12) | 0.69 (0.28–1.70) | |||||
a Values are the number of examined healthy women (controls) and those with HGSOC (cases). (%); b Adjusted analysis was carried out for HPV16 DNA copy number in whole-blood samples; c Adjusted analysis was carried out for HPV18 DNA copy number in whole-blood samples; OR: odds ratio; 95% CI: 95% confidence interval; p, logistic regression model; NA: not available; PB. The significance level after Bonferroni’s correction for multiple testing was 0.017 (raw p-value/3).